We are live on ! Find out more
FCM

Farallon Capital Management Portfolio holdings

AUM $17.5B
1-Year Est. Return 50.95%
This Fund
S&P 500
This Quarter Est. Return
+11.25%
1 Year Est. Return
+50.95%
3 Year Est. Return
+148.38%
5 Year Est. Return
+206.05%
10 Year Est. Return
+1,475.31%
AUM
$23.8B
AUM Growth
+$2.95B
Cap. Flow
+$1.1B
Cap. Flow %
4.63%
Top 10 Hldgs %
44.66%
Holding
165
New
18
Increased
38
Reduced
31
Closed
20

Top Buys

Rank Stock Value
1
SPY icon
State Street SPDR S&P 500 ETF Trust
SPY
+$3.14B
2
AMZN icon
Amazon
AMZN
+$601M
3
AON icon
Aon
AON
+$226M
4
TMO icon
Thermo Fisher Scientific
TMO
+$145M
5
AZEK
The AZEK Co
AZEK
+$100M

Top Sells

Rank Stock Value
1
DFS
Discover Financial Services
DFS
+$816M
2
ITCI
Intra-Cellular Therapies Inc.
ITCI
+$403M
3
EXEL icon
Exelixis
EXEL
+$260M
4
MSFT icon
Microsoft
MSFT
+$234M
5
INTU icon
Intuit
INTU
+$205M

Sector Composition

Rank Sector Weight
1 Healthcare 32.61%
2 Technology 13.02%
3 Financials 8.98%
4 Communication Services 7.2%
5 Industrials 5.13%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
COR icon
101
Cencora
COR
$61.2B
$300K ﹤0.01%
1,000
– –
UTHR icon
102
United Therapeutics
UTHR
$23.1B
$287K ﹤0.01%
1,000
– –
TWST icon
103
Twist Bioscience
TWST
$7.25B
$281K ﹤0.01%
7,650
– –
MMSI icon
104
Merit Medical Systems
MMSI
$5.32B
$280K ﹤0.01%
3,000
– –
KRYS icon
105
Krystal Biotech
KRYS
$9.66B
$275K ﹤0.01%
2,000
– –
LIVN icon
106
LivaNova
LIVN
$4.2B
$270K ﹤0.01%
6,000
-31,000
-84% -$1.28M
GKOS icon
107
Glaukos
GKOS
$10.6B
$269K ﹤0.01%
2,600
– –
ONC
108
BeOne Medicines Ltd
ONC
$39.4B
$266K ﹤0.01%
1,100
– –
ACLX
109
DELISTED
Arcellx
ACLX
$263K ﹤0.01%
4,000
– –
SBRA icon
110
Sabra Healthcare REIT
SBRA
$5.37B
$258K ﹤0.01%
14,000
– –
GRFS
111
Grifois
GRFS
$5.4B
$253K ﹤0.01%
28,000
– –
ARWR icon
112
Arrowhead Research
ARWR
$12.4B
$250K ﹤0.01%
15,800
– –
SRRK icon
113
Scholar Rock
SRRK
$6.44B
$248K ﹤0.01%
7,000
– –
ASND icon
114
Ascendis Pharma A/S
ASND
$16.8B
$242K ﹤0.01%
1,400
– –
SWTX
115
DELISTED
SpringWorks Therapeutics
SWTX
$235K ﹤0.01%
5,000
-113,000
-96% -$5.03M
ANNAW
116
AleAnna Inc Warrant
ANNAW
$8.06M
$233K ﹤0.01%
990,000
– –
AKRO
117
DELISTED
Akero Therapeutics
AKRO
$213K ﹤0.01%
+4,000
New +$182K
CGON icon
118
CG Oncology
CGON
$6.66B
$208K ﹤0.01%
+8,000
New +$193K
BRKR icon
119
Bruker
BRKR
$8.14B
$206K ﹤0.01%
5,000
– –
QURE icon
120
uniQure
QURE
$3.22B
$195K ﹤0.01%
14,000
– –
IMVT icon
121
Immunovant
IMVT
$8.25B
$192K ﹤0.01%
12,000
– –
HR icon
122
Healthcare Realty
HR
$6.84B
$190K ﹤0.01%
12,000
– –
TVTX icon
123
Travere Therapeutics
TVTX
$5.78B
$178K ﹤0.01%
+12,000
New +$199K
PACB icon
124
Pacific Biosciences
PACB
$368M
$167K ﹤0.01%
135,000
– –
EVH icon
125
Evolent Health
EVH
$447M
$158K ﹤0.01%
14,000
– –
3 4
5
6 7

Similar funds

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
MCM
MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return
LA
Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return
CM
Caption Management Oklahoma City, Oklahoma $17.1B AUM 70.99% 1-Year Est. Return
ASRS
Arizona State Retirement System Phoenix, Arizona $17.1B AUM 30.52% 1-Year Est. Return
PP
Prudential plc London, England, United Kingdom $17.1B AUM 15.7% 1-Year Est. Return
VMPIC
Varma Mutual Pension Insurance Co Helsinki, Finland $17B AUM 24.09% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Farallon Capital Management's Q2 2025 Portfolio in Review

As of Q2 2025, Farallon Capital Management held 165 positions worth $23.8B, up 14% from $20.9B the previous quarter. Its ten largest holdings account for 45% of the portfolio.

Farallon Capital Management deployed $1.1B of net new capital in Q2 2025, opening 18 new positions and adding to 38 existing holdings. Its largest new stake was State Street SPDR S&P 500 ETF Trust: 5,500,000 shares worth $3.4B.

By sector, the portfolio is most concentrated in Healthcare at 33% of assets, down from 38% a quarter earlier, followed by Technology and Financials.

On the sell side, the largest reduction was Exelixis, an estimated $260M trimmed.

  • Farallon Capital Management's largest Q2 2025 buy was State Street SPDR S&P 500 ETF Trust: 5,500,000 shares worth $3.4B.
  • Farallon Capital Management added most to Aon in Q2 2025, an estimated $226M increase.
  • Farallon Capital Management's biggest Q2 2025 reduction was Exelixis, cutting an estimated $260M.
  • Farallon Capital Management fully exited Discover Financial Services in Q2 2025, selling an estimated $816M.
  • Farallon Capital Management's ten largest holdings make up 45% of its $23.8B portfolio in Q2 2025.
  • Farallon Capital Management opened 18 new positions and closed 20 in Q2 2025.
  • Farallon Capital Management's portfolio value rose 14% quarter-over-quarter to $23.8B.

Based on Farallon Capital Management's 13F filing for Q2 2025, filed 14 Aug 2025.